Wave Life Sciences: director Mark Corrigan received 74,700 shares

What happened Mark Corrigan, director, was granted 10,700 restricted stock units (RSUs) and an option for 64,000 shares on Oct 5, 2026. Both grants are reported as acquisitions at $0.00; the option is reported as a derivative award.

Key details

• Transaction date: Oct 5, 2026. Form 4 filed Oct 7, 2026.
• Transaction codes: A (award/grant) for both grants; one grant reported as derivative (option).
• Price: $0.00 for the 10,700 RSUs and $0.00 for the option covering 64,000 shares.
• Shares owned after the transaction: not disclosed in this filing.
• Vesting (footnotes): RSU vests 100% on the earlier of the company's 2027 annual meeting or Oct 5, 2027 (F1). Option vests 100% on the earlier of the company's 2027 annual meeting or Oct 5, 2027 (F2).
• Corporate remark: On Aug 7, 2026, Wave Life Sciences, Inc. became successor to Wave Life Sciences Ltd. pursuant to a redomiciliation, as stated in the filing.
• Exhibit: Exhibit 24.1 power of attorney included.

Why it may matter These entries are compensation grants: an RSU award and an option grant (derivative), not market purchases or sales and not an option exercise. This filing does not show why the insider traded or why the company acted.